Supplemental material
Human Vaccines & Immunotherapeutics
Volume 19, 2023 - Issue 1
Meningococcal
Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
Corwin A. Robertsona Scientific & Medical Affairs, Sanofi, Swiftwater, PA, USACorrespondence[email protected]
https://orcid.org/0000-0002-3462-7368View further author information
https://orcid.org/0000-0002-3462-7368View further author information, Jeffry Jacqmeinb Jacksonville Center for Clinical Research, Jacksonville, FL, USAhttps://orcid.org/0000-0002-6887-7939View further author information
https://orcid.org/0000-0002-6887-7939View further author information, Alexandre Selmanic Biostatistics, Sanofi, Swiftwater, PA, USAhttps://orcid.org/0000-0002-7709-0142View further author information
https://orcid.org/0000-0002-7709-0142View further author information, Katherine Galarzaa Scientific & Medical Affairs, Sanofi, Swiftwater, PA, USAhttps://orcid.org/0000-0003-4950-9425View further author information
https://orcid.org/0000-0003-4950-9425View further author information & Philipp Osterd Global Medical Affairs, Sanofi, Lyon, Francehttps://orcid.org/0000-0002-9218-2395View further author information
https://orcid.org/0000-0002-9218-2395View further author information